RedHill Biopharma (RDHL) Short term Debt (2022)
RedHill Biopharma (RDHL) posted quarterly Short term Debt of $115.2 million for Q4 2022, up 34.75% quarter-over-quarter from $85.5 million in Q2 2022.
RedHill Biopharma (RDHL) Short term Debt (2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Short term Debt for 1 consecutive years, with $115.2 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Short term Debt changed N/A year-over-year to $115.2 million; the TTM figure through Dec 2022 stood at $115.2 million (changed N/A YoY), while the FY2022 annual figure was $115.2 million, changed N/A from the prior year.
- Short term Debt advanced to $115.2 million in Q4 2022 per RDHL's latest filing, from $85.5 million in the prior quarter.
- Across five years, Short term Debt topped out at $115.2 million in Q4 2022 and bottomed at $85.5 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 115.22 Mn |
| Jun 30, 2022 | 85.51 Mn |